HIGHLIGHTS
- who: Waander L. van Heerde from the Maastricht University Medical Centre have published the Article: Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases, in the Journal: (JOURNAL)
- what: For bleeding disorders, the main focus will lay on HA, as this is the most prevalent coagulation related bleeding disorder. This study showed that individualized dosing of FVIII replacement therapy based on ETP is superior in bleeding outcomes with this specific FVIII product.
- how: Showed that thrombin potential in emicizumab treated HA patients reached a plateau at 20-30% of normal which . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.